Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

T cell recognition of novel shared breast cancer antigens is frequently observed in peripheral blood of breast cancer patients

Research output: Contribution to journalJournal articleResearchpeer-review

  1. The metabolic enzyme arginase-2 is a potential target for novel immune modulatory vaccines

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Staphylococcus aureus alpha-toxin inhibits CD8+ T cell-mediated killing of cancer cells in cutaneous T-cell lymphoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Neo-antigen specific memory T-cell responses in healthy individuals

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Immunoprofiles of colorectal cancer from Lynch syndrome

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Staphylococcal alpha-toxin tilts the balance between malignant and non-malignant CD4+ T cells in cutaneous T-cell lymphoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Lynch syndrome-associated epithelial ovarian cancer and its immunological profile

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. The capacity of CD4+ Vγ9Vδ2 T cells to kill cancer cells correlates with co-expression of CD56

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Advances within cancer immunotherapy have fueled a paradigm shift in cancer treatment, resulting in increasing numbers of cancer types benefitting from novel treatment options. Despite originally being considered an immunologically silent malignancy, recent studies encourage the research of breast cancer immunogenicity to evaluate immunotherapy as a treatment strategy. However, the epitope landscape in breast cancer is minimally described, limiting the options for antigen-specific, targeted strategies. Aromatase, never in mitosis A-related kinase 3 (NEK3), protein inhibitor of activated STAT3 (PIAS3), and prolactin are known as upregulated proteins in breast cancer. In the present study, these four proteins are identified as novel T cell targets in breast cancer. From the four proteins, 147 peptides were determined to bind HLA-A*0201 and -B*0702 using a combined in silico/in vitro affinity screening. T cell recognition of all 147 peptide-HLA-A*0201/-B*0702 combinations was assessed through the use of a novel high-throughput method utilizing DNA barcode labeled multimers. T cell recognition of sequences within all four proteins was demonstrated in peripheral blood of patients, and significantly more T cell responses were detected in patients compared to healthy donors for both HLA-A*0201 and -B*0702. Notably, several of the identified responses were directed toward peptides, with a predicted low or intermediate binding affinity. This demonstrates the importance of including low-affinity binders in the search for epitopes within shared tumor associated antigens (TAAs), as these might be less subject to immune tolerance mechanisms. The study presents four novel TAAs containing multiple possible targets for immunotherapy of breast cancer.

Original languageEnglish
Article numbere1663107
JournalOncoImmunology
Volume8
Issue number12
Pages (from-to)e1663107
ISSN2162-4011
DOIs
Publication statusPublished - 2019

    Research areas

  • Breast cancer, breast cancer immunogenicity, immunomonitoring, overexpression antigens, shared tumor antigens, TAAs, TAAs in breast cancer, tumor associated antigens, tumor specific CD8+ T cells, tumor specific cytotoxic T cells

ID: 58520887